Amit Garg, MD
Dermatology · New Hyde Park, NYNPI 1245211127
Payments from drug & device makers
Across 427 payments — averaging $2743.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$464K
- AbbVie$182K
- Novartis$157K
- UCB SA$61K
- Insmed, Inc.$60K
- UCB, Inc.$57K
- plus $190K from 25 others
Across 61 payments — averaging $1241.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$39K
- Novartis$23K
- UCB, Inc.$9K
- Pfizer$4K
- Novartis Pharma AG$1K
What the payments were for
- Consulting fees$373,24882%
- Speaking & faculty fees$22,9955%
- Travel & lodging$49,15811%
- Food & beverage$7,3122%
- Education$1120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 70 | $464,222 |
| AbbVie | 58 | $182,224 |
| Novartis | 78 | $157,049 |
| UCB SA | 26 | $60,597 |
| Insmed, Inc. | 18 | $59,815 |
| UCB, Inc. | 63 | $57,353 |
| Boehringer Ingelheim | 20 | $36,076 |
| Novartis Pharma AG | 16 | $33,256 |
| Regeneron | 1 | $25,548 |
| Boehringer Ingelheim International GmbH | 15 | $16,904 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 10 | $13,723 |
| Sanofi US Services Inc. | 4 | $10,994 |
| E.r. Squibb & Sons, L.L.C. | 5 | $8,341 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $7,480 |
| Johnson & Johnson | 9 | $7,057 |
| Almirall LLC | 4 | $5,248 |
| Sanofi | 3 | $4,631 |
| UCB Biosciences Inc. | 3 | $4,108 |
| LEO Pharma AS | 1 | $3,560 |
| Pfizer | 2 | $3,325 |
| Galderma Laboratories, L.p. | 3 | $3,132 |
| Janssen Global Services, LLC | 1 | $3,100 |
| Amgen | 6 | $2,793 |
| Merck | 1 | $763 |
| Dermavant Sciences, Inc. | 1 | $57 |
| Sun Pharmaceutical Industries Inc. | 1 | $57 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $31 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Sandoz | 1 | $19 |
| Bristol Myers Squibb | 1 | $17 |
| UCB GmbH | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,171,517 in reported general payments places this provider in the 95th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Sensoready (2 Pens)Secukinumab | 31 | $292,800 |
| TremfyaGuselkumab | 21 | $265,405 |
| Humira(Cf) PenAdalimumab | 12 | $194,385 |
| Taltz AutoinjectorIxekizumab | 14 | $87,042 |
| RenflexisInfliximab-Abda | 12 | $53,827 |
| Dupixent PenDupilumab | 14 | $53,522 |
| Acitretin | 11 | $8,896 |
| Triamcinolone Acetonide | 102 | $1,587 |
| Tacrolimus | 11 | $1,574 |
| Clobetasol Propionate | 31 | $1,552 |
| Mycophenolate Mofetil | 24 | $1,390 |
| Ketoconazole | 48 | $1,315 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 15 | $976 |
| Betamethasone Dipropionate | 28 | $951 |
| Fluorouracil | 17 | $877 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $7,057 | $265,40521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,151 dermatology providers in New York.
Other dermatology in New Hyde Park
- Emma GuttmanNew York$35.3M
- Saakshi KhattriNew York$15.4M
- James KruegerNew York$6.3M
- Michael CameronNew York$5.8M
- Mark LebwohlNew York$5.8M
- Andrew AlexisNew York$5.7M
- John TuRochester$5.4M
- Jeffrey WeinbergKew Gardens$4.9M
- Neil SadickNew York$4.2M
- Alice GottliebSomers$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.